Clinical Trial Update: Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dacarbazine with or without oblimersen in advanced malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Oblimersen (oblimersen)

Snippet

Sponsor: Genta Incorporated | Conditions: Melanoma (Skin) | Phase 3 | Status: COMPLETED